Owners, management and financials
CVR: 41696451
DKK -53,859,865
Gross profit
Net result: DKK -55,785,767
HELLERUNG ApS (25-33,32%), INVIVO VENTURES III, FCRE (10-14,99%)
2 more
CVR · view owners
Ellen Kinson Donnelly
Board: Luis Garcia Pareras (chair) and 5 members
CVR · view management
Active
Founded 21 September 2020
CVR · view overview
10 employees
Annual report 2025 · average
Director role ended: Janine Terra Erler
CVR · 15/09/2025
View the full event history
Neumirna Therapeutics ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ellen Kinson Donnelly. The board consists of Luis Garcia Pareras (chair), Andreas Wallnöfer, Ellen Kinson Donnelly and Francesco Paolo Di Giorgio. The company's owners include HELLERUNG ApS, INVIVO VENTURES III, FCRE and Angelini Ventures S.p.A.. According to the 2025 annual report, the company had an average of 10 employees. In 2025, the company reported a gross profit of DKK -53,859,865 and a net result of DKK -55,785,767 compared with DKK -6,954,201 the year before. Equity in the 2025 report amounted to DKK 91,816,175.
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -53.9 mio. | -55.8 mio. | 100.4 mio. | 91.8 mio. | 10 | |
| 202401/01/2024 – 31/12/2024 | -5.5 mio. | -7 mio. | 5.5 mio. | -18.4 mio. | 5 | |
| 202301/01/2023 – 31/12/2023 | -5.5 mio. | -8 mio. | 6.3 mio. | -11.5 mio. | 3 | |
| 202201/01/2022 – 31/12/2022 | -4.7 mio. | -5.3 mio. | 9 mio. | -3.4 mio. | 3 |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of Neumirna Therapeutics ApS is 41696451.
The owners of Neumirna Therapeutics ApS include HELLERUNG ApS, INVIVO VENTURES III, FCRE and Angelini Ventures S.p.A..
The management of Neumirna Therapeutics ApS consists of Ellen Kinson Donnelly.
The board of Neumirna Therapeutics ApS consists of Luis Garcia Pareras, Andreas Wallnöfer and Ellen Kinson Donnelly, with Luis Garcia Pareras as chair.
In 2025, Neumirna Therapeutics ApS reported a gross profit of DKK -53,859,865.
Neumirna Therapeutics ApS had an average of 10 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Neumirna Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -53,859,865, and the net result was DKK -55,785,767.
As of April 7, 2026, Francesco Paolo Di Giorgio has joined the board of directors of Neumirna Therapeutics ApS.
As of April 7, 2026, Thomas Michael Thestrup has left the board of directors of Neumirna Therapeutics ApS.
As of September 15, 2025, Ellen Kinson Donnelly has joined the board of directors of Neumirna Therapeutics ApS.
As of September 15, 2025, Ellen Kinson Donnelly is registered as adm. dir. of Neumirna Therapeutics ApS.
As of September 15, 2025, Janine Terra Erler has stepped down as adm. dir. of Neumirna Therapeutics ApS.
As of August 11, 2025, is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 10%.
As of August 11, 2025, is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 15%.
Neumirna Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -5,495,935, and the net result was DKK -6,954,201.
As of June 27, 2025, EY Godkendt Revisionspartnerselskab has been appointed auditor of Neumirna Therapeutics ApS.
As of June 27, 2025, Beierholm Godkendt Revisionspartnerselskab has stepped down as auditor of Neumirna Therapeutics ApS.
As of May 15, 2025, HELLERUNG ApS is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 25%.
As of May 15, 2025, is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 15%.
As of March 24, 2025, Andreas Wallnöfer has joined the board of directors of Neumirna Therapeutics ApS.
As of January 10, 2025, Luis Garcia Pareras has joined the board of directors of Neumirna Therapeutics ApS.
As of January 10, 2025, Thomas Michael Thestrup has joined the board of directors of Neumirna Therapeutics ApS.
As of January 10, 2025, Sten Verland has left the board of directors of Neumirna Therapeutics ApS.
As of January 10, 2025, Mads Spangaard Rasmussen has left the board of directors of Neumirna Therapeutics ApS.
As of January 10, 2025, Markus Sakari Kauppinen has left the board of directors of Neumirna Therapeutics ApS.
As of January 10, 2025, Lars Hellerung Christiansen has left the board of directors of Neumirna Therapeutics ApS.
Neumirna Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -5,476,181, and the net result was DKK -8,034,417.
As of November 1, 2023, Janine Terra Erler is registered as adm. dir. of Neumirna Therapeutics ApS.
As of November 1, 2023, Henrik Valdemar Klitgaard has stepped down as adm. dir. of Neumirna Therapeutics ApS.
Neumirna Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -4,660,603, and the net result was DKK -5,292,246.
As of January 2, 2023, Milla Koistinaho has joined the board of directors of Neumirna Therapeutics ApS.
As of November 9, 2022, Sten Verland has joined the board of directors of Neumirna Therapeutics ApS.
As of November 9, 2022, Mads Spangaard Rasmussen has joined the board of directors of Neumirna Therapeutics ApS.
As of November 8, 2022, Mads Spangaard Rasmussen has left the board of directors of Neumirna Therapeutics ApS.
Neumirna Therapeutics ApS has published its interim report for the period September 21, 2020 – December 31, 2021.
As of October 12, 2021, Morten Priskorn has left the board of directors of Neumirna Therapeutics ApS.
As of June 18, 2021, Mads Spangaard Rasmussen has joined the board of directors of Neumirna Therapeutics ApS.
As of June 18, 2021, Wyle Solomon has left the board of directors of Neumirna Therapeutics ApS.
As of June 17, 2021, Mads Spangaard Rasmussen has left the board of directors of Neumirna Therapeutics ApS.
As of December 11, 2020, Lars Hellerung Christiansen has joined the board of directors of Neumirna Therapeutics ApS.
As of December 11, 2020, Wyle Solomon has joined the board of directors of Neumirna Therapeutics ApS.
As of December 10, 2020, Lars Hellerung Christiansen has left the board of directors of Neumirna Therapeutics ApS.
As of September 21, 2020, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Neumirna Therapeutics ApS.
As of September 21, 2020, Mads Spangaard Rasmussen has joined the board of directors of Neumirna Therapeutics ApS.
As of September 21, 2020, Markus Sakari Kauppinen has joined the board of directors of Neumirna Therapeutics ApS.
As of September 21, 2020, Lars Hellerung Christiansen has joined the board of directors of Neumirna Therapeutics ApS.
As of September 21, 2020, Morten Priskorn has joined the board of directors of Neumirna Therapeutics ApS.
As of September 21, 2020, Henrik Valdemar Klitgaard has joined the board of directors of Neumirna Therapeutics ApS.
As of September 21, 2020, Henrik Valdemar Klitgaard is registered as adm. dir. of Neumirna Therapeutics ApS.
Neumirna Therapeutics ApS was founded on September 21, 2020.
Companies in the same industry and area
CVR 19352102
CVR 44931885
CVR 44214032
CVR 46763904
CVR 37065226
